Reply to A. Wang-Gillam et al

J Clin Oncol. 2017 Feb 20;35(6):690-691. doi: 10.1200/JCO.2016.70.7463. Epub 2016 Dec 5.

Authors

Davendra P S Sohal¹, Pamela B Mangu¹, Daniel Laheru¹, Alok A Khorana¹

Affiliation

¹ Davendra P.S. Sohal, Cleveland Clinic, Cleveland, OH; Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; Daniel Laheru, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; and Alok A. Khorana, Cleveland Clinic, Cleveland, OH.

PMID: 27918714
DOI: 10.1200/JCO.2016.70.7463

No abstract available

Publication types

Letter
Comment

MeSH terms

Humans
Irinotecan
Neoplasms, Second Primary*
Pancreatic Neoplasms*
Topoisomerase I Inhibitors

Substances

Topoisomerase I Inhibitors
Irinotecan